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Abstract. A 1,2,3-triazole-based RGD peptidomimetic having nanomolar affinity for αvβ3 integrin was conjugated to 
the potent antimitotic paclitaxel via an oxime heterobifunctional linker. The resulting construct maintained 
nanomolar binding concentration to αvβ3 integrin and showed 11-fold selectivity in terms of cytotoxicity towards 
highly αvβ3 expressing U87MG cancer cells relative to non αvβ3 expressing MCF7 cells, indicating promising cancer 
cell targeting capacity. 
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The efficacy of chemotherapeutic agents clinically used for the treatment of malignant tumours is generally limited 
by their non-specific toxicity against off-target cells, especially those characterised by a high proliferation rate, 
resulting in a reduced therapeutic index and serious side effects (e.g. alopecia, nausea, vomiting and 
immunosuppression). Several strategies have been developed over the years in order to overcome these problems 
and achieve a tumour-targeted delivery of cytotoxic agents.1 An attractive approach is represented by hybrid 
compounds, containing a cytotoxic drug bound to a moiety that specifically identifies protein markers overexpressed 
on cancer cells. Thanks to the development of phage display technologies, several peptide sequences capable of 
recognising tumour markers have been discovered and extensively investigated as valuable tools for tumour-targeted 
delivery of chemotherapeutics.1-2 RGD-containing peptides targeting αvβ3 integrin belong to this class of tumour-
homing vectors. The overexpression of αvβ3 on solid tumours, along with its capacity to be internalised via endocytosis 
after binding of ligands such as RGD peptides, makes it an attractive target for tumour delivery of anticancer agents.3 
A number of cytotoxic drugs have been conjugated to tumour-homing peptides containing the RGD motif and the 
resulting constructs assessed in animal models. Several studies in this field provided experimental evidence that RGD-
based strategies contribute to reduce the toxicity and augment the therapeutic window of existing 
chemotherapeutics.1,4,5  
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 Figure 1. Structure of the RGD parent peptide and a triazole-based RGD peptidomimetic (1).6 The chemical groups mimicking the arginine (R), glycine (G) and aspartate 
(D) amino acids are coloured in blue, green and red, respectively. 
 
In previous studies we have described the rational design of a new class of integrin ligands based on a triazole scaffold 
that led to the discovery of RGD peptidomimetics highly active for αvβ3 and selective against the platelet receptor αIIbβ3 
(compound 1, Figure 1).6 Herein, we report the design and synthesis of a 1,2,3-triazole-based RGD peptidomimetic 
conjugated with the potent antimitotic agent paclitaxel (PTX), and its selectivity (11-fold) towards αvβ3 expressing 
cells relative to PTX alone. 
Design.  An important feature of RGD-cytotoxic conjugates is that, once internalised into the target cells, they should 
be promptly disassembled resulting in the release of the cytotoxic agent. Derivatives characterised by an excessive 
stability could irreversibly impair the therapeutic activity of the parent drug. On the other hand, functionalities that 
prematurely release the chemotherapeutic agent by metabolic or chemical breakdown, will compromise the targeted 
delivery strategy resulting in off-target toxicity. Usually, amides, hydrazides, carbamates and sterically hindered 
esters are used to connect the cytotoxic drug to the tumour-homing moiety through a linker.4,7 Conjugation of PTX to 
RGD ligands could be performed via cleavable succinyl ester linker attached to the 2′-OH group of PTX (Scheme 1). As 
the 2′-OH function is essential for PTX to exert its cytotoxic and microtubule-stabilising activities, it should be easily 
released from the ester function once delivered to the target organ.8 It has been shown that the succinyl ester bond at 
the PTX-2′ position is sufficiently stable to guarantee tumour-selective delivery of RGD-PTX conjugates and is 
enzymatically cleaved in vivo by esterases to provide PTX into its active form.4 While the cytotoxic agent is converted 
into an inactive prodrug by coupling to an RGD carrier, the RGD-ligand should maintain its capacity to bind the αvβ3 
receptor when attached to the cytotoxic payload. In this regard, SAR studies conducted on triazole-based RGD 
mimetics6 provided essential information for the rational design of active derivatives functionalised with a handle 
necessary for the ligation of the cytotoxic cargo. We have demonstrated that the functional moieties of this class of 
ligands mainly responsible for integrin recognition are (i) the carboxylic function, (ii) the sulfonamide group, (iii) the 
electron withdrawing substituents on the phenyl ring and (iv) the basic 2-aminopyridine (Figure 2). Conversely, the 
triazole ring, lying at the interface between the α and β subunits, acts as a spacer between the major functional groups 
involved in ligand-receptor interactions and, therefore, it appears to be the most suitable site for functionalisation. 
Noteworthy is the fact that incorporation of a bulky substituent - like iodine - in position 5 of the triazole ring did not 
affect the binding properties of this class of ligands.6 Taking into account all of these aspects, we designed the 
construct 3 formed by (i) PTX-2′-succinate, (ii) the RGD mimetic 1 equipped with a chemical handle on the triazole 
ring and (iii) a heterobifunctional linker 4 connecting these two portions (Scheme 1).  
Retrosynthesis. The synthesis of conjugate 3 is based on the convergent assembly of three building blocks (Scheme 
1): (i) the PTX-2′-succinate activated as N-hydroxysuccinimide (NHS) ester 2, (ii) the RGD ligand functionalised with 
a chemical handle bearing an aldehyde function 5 and (iii) the heterobifunctional linker 4-(aminooxy)butan-1-amine 
4. Based on our retrosynthetic plan (Scheme 1), the aldehyde 5 can be generated by oxidation of the key intermediate 
alcohol 6 obtained connecting the iodinated precursor 7 and 4-pentynol 8 via Sonogashira cross-coupling (Scheme 
1).  
  
Figure 2. Predicted binding mode of triazole-based RGD peptidomimetics on integrin αvβ3 (top).6 The functional groups involved in the ligand-receptor recognition 
process are circled in red (bottom). The position 5 of the triazole ring (blue circle) has been selected as a suitable position for the attachment of the cytotoxic 
payload.  
Scheme 1. Retrosynthetic approach to the target conjugate 3. 
 
Synthesis. For the synthesis of the building block PTX-2′-succinate-NHS ester 2 (Scheme 1), the 2′-hydroxyl function 
of PTX was derivatised with succinic anhydride following a procedure reported in literature.9 The resulting PTX-
succinate was activated as NHS ester 2 using N,N′-dicyclohexylcarbodiimide (DCC) as coupling reagent, as already 
described.9 
The key RGD intermediate 6 (Scheme 2) was synthesised via Sonogashira cross-coupling between the iodinated 
precursor 7 and 4-pentyn-1-ol 8. A number of conditions were explored (Table 1). Application of typical Sonogashira 
protocol on this substrate (phosphine-ligated Pd catalyst, CuI as co-catalyst and an amine as a base)10 afforded no 
reaction at room temperature and decomposition at higher temperatures (entries 1–4). Similarly, following a ligand-
, copper- and amine- free strategy reported by Urgaonkar and Verkade, based on the use of Pd acetate (Pd(OAc)2) and 
tetrabutylammonium acetate (Bu4NOAc) as a base,11 no reaction was observed at r.t. (entry 5). By increasing the 
temperature no decomposition occurred, although only starting material was recovered (entry 6). Addition of TEA to 
Pd(OAc)2 and Bu4NOAc gave rise to the formation of trace amounts of 6 at 60 °C after 6 hours (entry 7). Using TEA (3 
equiv) and a large excess of alkyne (10 equiv) the desired alkynylated product 6 was eventually obtained in good 
yields (70%) in less than 6 hours (entry 8).12 
 
Scheme 2. Synthesis of 6 via Sonogashira cross-coupling. 
Table 1. Reaction conditions tested for Sonogashira cross-coupling  
Entry Catalyst 8  
(equiv) 
Temp 
(h) 
base Time Yielda 
1 Pd(PPh3)4+CuI 1 25 TEA 12 NR 
2 Pd(PPh3)4+CuI 1 60 TEA 6 D 
3 Pd(PPh3)2Cl2+CuI 1 25 TEA 12 NR 
4 Pd(PPh3)2Cl2+CuI 1 60 TEA 6 D 
5 Pd(OAc)2 1.25 25 Bu4NOAc 12 NR 
6 Pd(OAc)2 1.25 60 Bu4NOAc 12 NR 
7 Pd(OAc)2 1.25 60 Bu4NOAc
+TEA 
6 low 
yield 
8 Pd(OAc)2 10 60 Bu4NOAc
+TEA 
12 70 % 
aThe reaction course was monitored via RP-HPLC coupled to tandem ESI-MS. 
NR = no reaction, starting material recovered; D = decomposition 
 
The heterobifunctional linker 4 (Scheme 3) was synthesised starting from 1-bromo-4-cloro butane 9 that, reacting 
with sodium azide at room temperature in DMF, afforded 1-cloro-4-azido butane 10. Treatment of 10 with N-Boc 
protected hydroxylamine in the presence of a base led to the formation of 11, which was converted into the amino 
derivative 12 by Staudinger reaction. N-Boc cleavage of 12 with TFA afforded the final product 4 in good overall 
yields. The assembly of the conjugate 3 was straightforward (Scheme 4). Conversion of alcohol 6 into aldehyde 5 was 
performed under mild conditions using Dess-Martin periodinane (DMP) reagent. The reaction was monitored by RP-
HPLC coupled to tandem ESI-MS. After total consumption of the starting material 6, the heterobifunctional linker 4 
was added to the same reaction flask generating the intermediate 13 via chemoselective oxime bond formation.13 
Purification of 13 was performed by semipreparative RP-HPLC. The free amino function of 13 was then reacted with 
PTX-2′-succinate-NHS ester 2 in the presence of DIPEA to provide the final conjugate 3 in 54% yield after 
chromatographic purification.  
 
Scheme 3. Synthesis of 4. Reagents and conditions: (i) NaN3, DMF, room temp, overnight, 99%; (ii) BocNHOH, DBU, DMF, room temp, 2h, 40%; (iii) PPh3, THF, room 
temp, 1h then H2O, 60 °C, 4h, 99%; (iv) TFA-CH2Cl2 (1:1), rt, 2h, 99%. 
 Scheme 4. Synthesis of 3. Reagents and conditions: (i) DMP, CH3CN, room temp, 6h, then (ii) 4, room temp, 1h, 60%; (iii) DIPEA, DMF, room temp, 5h, 54%. 
 
Solid-phase receptor binding assay. The RGD mimetic 6 functionalised with a chemical handle and the conjugate 
construct 3 were submitted to biological assays to measure their affinity for the αvβ3 receptor. Competitive affinities 
were calculated analysing the interactions between immobilised αvβ3 and the commercially available c[RGDfK(Biotin-
PEG-PEG)] peptide in the presence of increasing amounts of ligands, as already described.15 The IC50 values of 6 and 
3 were compared to that of the non-functionalised peptidomimetic 1 and the αvβ3-inhibitor c(RGDfK) (Table 2). 
Notably, functionalisation of the highly active RGD mimetic 1 with an alkynyl chemical handle to give the derivative 6 
was performed without perturbing the binding affinity of the parent ligand (Table 2, entries 2 and 3). Conversely, the 
large increase of steric hindrance in the conjugate 3 caused a ~10-fold drop in binding affinity (Table 2, entries 2 and 
4). However, the IC50 value of 3 was still in the nanomolar range and not significantly different from that of the 
reference c(RGDfK) peptide used as positive control (Table 2, entries 1 and 4).  
 
Table 2 Inhibition of cyclo[RGDfK(Biotin-PEG-PEG)] binding to immobilised αvβ3. 
entry compound IC50 (nM)a 
1 c(RGDfK) 138 ± 51 
2 1 25 ± 3 
3 6 20 ± 1 
4 3 200 ± 46 
aData are the average of two independent experiments performed in triplicate; standard deviations are shown 
 
Cell cytotoxicity assays. Conjugate 3 was tested in vitro to assess its cytotoxicity towards MCF7 and U87MG tumour 
cells, which express no and high levels of αvβ3 integrin, respectively. The unconjugated ligand 1 and free PTX were 
also included in the study. In order to reliably assess the selective cytotoxicity of conjugate 3 against αvβ3 positive cell 
lines, a “cell washout” cytotoxicity assay was performed.16 Following this procedure - aimed at mimicking the in vivo 
conditions where the administered drug is rapidly cleared from the extracellular tumour environment - cells were 
incubated with the cytotoxic agents for a short period of time (6 h) and then the medium was washed away to remove 
the non-internalised conjugate 3. Using this method, the possible anti-proliferative activity arising from extracellular 
cleavage of the linker from 3 - and consequent undesired drug release - can be minimised.17 As expected, cytotoxicity 
assays clearly indicated that the tumour-homing peptidomimetic 1 was not cytotoxic (Table 3) when used at 
concentrations up to 10,000 nM. In contrast, PTX was potently cytotoxic to both cell lines, as a result of its capacity to 
readily enter the cells and inhibit microtubule disassembly. Conjugate 3 was also cytotoxic for both cell lines, although 
IC50 values were considerably higher than for PTX, indicating that the construct was not hydrolysed and did not 
release free PTX during incubation.  
 
Table 3 Cell sensitivity of U87MG and MCF7 tumour cells to PTX, 3 and 1 
Cell line Compound 1 
IC50 (nM)a 
Compound 3 
IC50 (nM)a 
PTX IC50 
(nM) a 
MCF7 
(αvβ3-) 
> 10, 000 21.6∙103 ± 
10.6∙103 
41.3 ± 14  
U87MG 
(αvβ3++) 
> 10, 000 1.99∙103 ± 
1.59∙103 
44.4 ± 26 
Selectivityc - 11 1.0 
a IC50 values were calculated as the concentration of compound required for 50% inhibition of cell viability in culture. The number of cells in each well was measured using an (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay, as described [ref. 18]; 
bCytotoxicity ratio for U87MG vs MCF7 is statistically significant; (p value <0.01 in one way ANOVA). Compound 1 exhibited no significant cytotoxicity when tested at concentrations 
up 10,000 nM. 
C Selectivity: IC50(αvβ3)/IC50(αvβ3++). 
 
As expected, PTX was not αvβ3-selective, showing essentially the same IC50 on both highly αvβ3 integrin expressing 
cells (U87MG) and non-expressing cells (MCF7). In contrast, the conjugate 3 showed good selectivity index = 11 
(determined by the IC50(MCF7)/IC50(U87MG) ratio), indicating a higher cytotoxicity for U87MG vs. MCF7 cells. This is 
consistent with the hypothesis that compound 3 can selectively target cancer cells via αvβ3 integrin.  
 
Metabolic stability assays.19 The conjugate 3 and the RGD mimetic 1 were subjected to human and rat liver 
microsomal stability tests to determine in vitro their stability towards cytochrome P (CYP)-mediated metabolism. 
Test compounds were incubated with rat and human microsomes at 37 °C in the presence of the co-factor NADPH. 
The reaction was terminated by the addition of methanol. Following centrifugation, the supernatant was analysed on 
the LC-MS/MS. From this study emerged that both the tumour-homing moiety 1 and the cytotoxic construct 3 were 
considerably stable both in human and rat microsome suspensions (half-life 770 and 470 min, respectively). The fate 
of the conjugate 3 upon incubation with U87MG cells was also investigated. HPLC/MS analysis and 19F NMR 
spectroscopy of both cell lysate and culture medium confirmed that after 24 hours the conjugate 3 is still present 
unchanged, whereas a minor HPLC peak corresponding to free PTX could also be detected. This confirm the 
substantial stability of 3 and the slow release of PTX in the presence of cells,  
Conclusions. In this work, we described the rational design of a novel tumour-targeted cytotoxic conjugate 3 
incorporating the potent antimitotic paclitaxel (PTX). The triazole-based RGD mimetic 1 was designed as the tumour-
homing motif of the chemotherapeutic construct. The targeting vector 1 was then functionalised with a chemical 
handle on the triazole ring, which was identified as the most suitable site for derivatisation of the RGD mimetic 
scaffold. Measurement of the binding affinity of the functionalised mimetic 6 demonstrated that the alkynyl chain on 
the triazole ring did not affect the high affinity of 1 for αvβ3 integrin. The synthesis of the conjugate 3 was performed 
by linking the cytotoxic agent 2 and the RGD carrier 5 through a heterobifunctional linker 4. The strong increase of 
steric hindrance in the construct 3 caused a ~10-fold drop in binding affinity, however, the IC50 value of 3 remained 
in the nanomolar range and was not significantly different relative to that of the reference c(RGDfK) peptide. PTX and 
conjugate 3 were then tested in vitro to assess their cytotoxic activity towards MCF7 and U87MG tumour cells, which 
express no and high levels of αvβ3 integrin, respectively, using a “cell washout” assay. Under these conditions, PTX was 
found to be cytotoxic on both cell lines irrespectively of their αvβ3 integrin-expression level, while the cytotoxic 
activity of conjugate 3 was dependent on αvβ3 integrin expression. These results demonstrate the capacity of 3 to 
selectively deliver the cytotoxic paclitaxel cargo through αvβ3 integrin interaction. In vitro human and rat liver 
microsomal stability tests showed a remarkable stability of both conjugate 3 and RGD carrier 1 against CYP-mediated 
hepatic metabolism. Further studies will be performed in the future to assess the in vivo capacity of the conjugate 3 
to increase the therapeutic window and limit the peripheral toxicity of PTX.     
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